Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
- Update frequency
- every 7 days
- Average duration
- 37 minutes
- Episodes
- 164
- Years Active
- 2022 - 2025
AI in biotech today, and how it will impact the industry tomorrow
AI is driving innovation across industries, including biotech, but where is its influence felt most and what opportunities for future impact are emerging?
David del Bourgo is the co-founder and CEO of…
How nanobodies will revolutionize immunotherapy
From llamas and camels to humans worldwide. Nanobodies are enjoying success in the clinic and experts are hailing these camelid-derived biologics as one of the next big things in immunotherapy.
Kristi…
Meeting the global demand for cell therapies: scaling with smart manufacturing
Cell therapies are at the cutting edge of personalized medicine but as demand for these therapies grows, how will the industry scale manufacturing to meet patient needs?
Fabian Gerlinghaus is co-found…
Treating spinal cord injuries with stem cells
Spinal cord injuries impact millions of people worldwide and, unlike many chronic injuries, they usually arrive with no forewarning, impacting the young and old alike.
Brian Culley is CEO of Lineage C…
Are mitochondrial therapeutics about to go mainstream?
Mitochondria are famously the powerhouse of the cell, but will mitochondrial therapeutics power the next big mainstream medical breakthrough?
Klaus Dugi is CEO of Vandria, a biotech that develops mito…
Fighting Alzheimer's with innovative stem cell therapies
Regeneration Biomedical has developed a new technique to address neurodegenerative diseases like Alzheimer's using stem cell therapy.
Dr. Christopher Duma, has long been an innovator in neurosurgery u…
[Rebroadcast] How AI immune system mapping can boost drug discovery
We’re taking a short break this week and, while we’re away, we invite you to enjoy one of our favorite episodes. We will return with a brand-new episode next week!
Immunai is mapping the immune system…
The TCR-T cell therapies of tomorrow
Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with the TCR-T cell therapy trials called VIDAR-1.
The CEO, Reagan Jarvis, when a researcher…
Can RNA drugs solve the obesity epidemic?
Resalis Therapeutics is pursuing a groundbreaking approach to obesity treatment.
Unlike current therapies that primarily focus on appetite suppression, Resalis’ lead program, RES-010, is a non-coding …
Reversing cancer mechanisms to fight back against solid tumors
CatalYm is preparing to initiate its broad phase 2b clinical development program for visugromab to tackle multiple solid tumor indications.
Visugromab is a monoclonal antibody that neutralizes the tu…
Targeting the dark genome to develop new therapies to fight obesity
In the fall of 2024, Haya Therapeutics, based in Switzerland and San Diego, landed a $1bn deal with Eli Lilly to apply its long non-coding RNA (ncRNA) technology to obesity.
The company’s lead candida…
Can Tumor Activated Therapy kill solid tumors?
Solid tumors present a big challenge for current treatments. However, a new approach might provide the answers - Tumor Activated Therapy.
By targeting specific proteins common in all solid tumor micr…
J.P. Morgan Annual Healthcare Conference 2025: trends and highlights you may have missed
This week, we take a look at some of the highlights from the 43rd Annual J.P. Morgan Healthcare Conference, which took place in San Francisco recently.
While there weren’t necessarily many financial b…
Venture capital co-creation: The next big thing in biotech investment?
Jessica Owens and Iana Dimkova are co-founders of Initiate Ventures—a female-led venture capital firm and studio that launched recently with a $45 million debut fund.
Initiate Ventures is shaking up t…
Developing non-opioid pain drugs
Brixton Biosciences, a clinical-stage life sciences company spun out from Massachusetts General Brigham, has been awarded $2m from the NIH HEAL Initiative to support the development of non-opioid, in…
[Rebroadcast] The power of natural killer cells
While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on January 3rd, 2025! Have an awesome holiday season!
On th…
Looking at 2025 biotech trends with SoftBank Vision Fund
Our guest on the podcast this week is John Cassidy, director of life sciences and healthtech investments at SoftBank Vision Fund.
Softbank Vision Fund is the world’s largest technology-focused investm…
Finding new treatments for peanut allergy
There is a constant risk of severe, potentially life-threatening allergic reactions for individuals with peanut allergies, which leads to significant physical, social, and emotional burdens.
IgGenix, …
Cracking the code of biotech valuations
ambiom is a life science commercial-advisory business development company based in the Slovakian capital of Bratislava.
The company helps its corporate clients with their product strategy, in- and out…
Can biotech beat mosquito-borne diseases?
Biological control company Oxitec recently launched Sparks, a new platform designed to rapidly scale Wolbachia replacement technology to take on dengue fever.
Backed by a multi-million-dollar investme…